Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636067 | 0.90 | ADRB2 (0.51) | ADRB2ADRB1HTR1AOPRK1CREBBP | |
| SCHEMBL97840 | 0.90 | ADRB2 (0.51) | ADRB2ADRB1HTR1AOPRK1CREBBP | |
| SCHEMBL15283144 | 0.83 | MAPT (0.45) | MAPTADRB2ADRB1HTR1AOPRK1 | |
| SCHEMBL7730049 | 0.82 | MAPT (0.44) | MAPTADRB2ADRB1HTR1AOPRK1 | |
| SCHEMBL2267107 | 0.81 | DRD2 (0.50) | MAPTHTR1AOPRK1CREBBPKMT2A | |
| SCHEMBL20777506 | 0.81 | ALDH1A1 (0.43) | KMT2AMTNR1AALDH1A1CYP3A4 | |
| SCHEMBL8523665 | 0.80 | MAPT (0.55) | MAPTCREBBPKMT2ABRD4PARP1 | |
| SCHEMBL19301904 | 0.79 | CREBBP (0.45) | CREBBPKMT2ABRD4ACHETSHR | |
| SCHEMBL30116234 | 0.79 | CREBBP (0.45) | CREBBPKMT2ABRD4ACHETSHR | |
| SCHEMBL6583312 | 0.78 | DRD2 (0.45) | MAPTADRB2ADRB1HTR1AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| EP-3956334-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2025-09-24 | — | — | EP | disclosed |
| US-20230084690-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2023-03-16 | — | — | US | disclosed |
| EP-3956334-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | Merck Patent GmbH (DE) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020212543-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212543-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | WO | disclosed |
| US-10632119-B2 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor | CEPHALON, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190328735-A1 | Fused Bicyclic 2,4-Diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor | CEPHALON, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10259794-B2 | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives | CEPHALON, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-2661437-B1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008039520-A2 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-4340595-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-20 | — | — | US | disclosed |
| EP-0011747-B1 | AMINOPROPANOL DERIVATIVES OF 6-HYDROXY-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0011747-A1 | Aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-2-ones, process for their preparation, and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084690-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | PDE6C, UACA, PDE6A | MAPT 163/4885ADRB2 3067/4885ADRB1 3042/4885 |
| US-10632119-B2 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor | ALK, PTK2, ABL1 | MAPT 3222/4885ADRB2 3988/4885ADRB1 3891/4885 |
| US-20190328735-A1 | Fused Bicyclic 2,4-Diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor | ALK, PTK2, ABL1 | MAPT 3222/4885ADRB2 3988/4885ADRB1 3891/4885 |
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | MAPT 2956/4885ADRB2 598/4885ADRB1 227/4885 |
| US-10259794-B2 | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives | DPYD, LIG4, CEP170 | MAPT 2618/4885ADRB2 4738/4885ADRB1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.